Darwin Wealth Management’s Haemonetics HAE Stock Holding History

Darwin Wealth Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.11K	Buy	+58	New	+$5.4K	﹤0.01%	733

Other funds holding HAE

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

River Road Asset Management Louisville, Kentucky $8.42B AUM 5.65% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return

Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Darwin Wealth Management's HAE Position: Q3 2026 in Review

Darwin Wealth Management opened a new position in Haemonetics (HAE) in Q3 2026: 58 shares worth $6.11K. The stake represents ﹤0.01% of the portfolio and ranks #733 among its holdings.

185 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

Darwin Wealth Management held 58 shares of Haemonetics worth $6.11K as of Q3 2026.
Haemonetics was a new Darwin Wealth Management position in Q3 2026.
Haemonetics made up ﹤0.01% of Darwin Wealth Management's portfolio in Q3 2026, its #733 holding.
185 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on Darwin Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.